Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Armata Pharmaceuticals (ARMP) will deliver a corporate presentation at the H.C.

Rhea-AI Summary

Armata Pharmaceuticals (ARMP) will deliver a corporate presentation at the H.C. Wainwright 28th Annual Global Investment Conference in New York on September 16, 2026.

Chief Executive Officer Deborah Birx, M.D., is scheduled to present from 11:00 am to 11:30 am EDT on Wednesday, September 16, 2026. The company develops high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections and is advancing clinical phage candidates targeting Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens.

Key Terms

cGMP, bacteriophage therapeutics

2 terms

cGMP technical

"in-house phage-specific cGMP manufacturing to support full commercialization"

cGMP (current Good Manufacturing Practice) are government-enforced quality standards that manufacturers must follow to ensure drugs, medical devices, and related products are made consistently, safely, and meet specified quality tests. For investors, cGMP compliance is like a restaurant passing health inspections: it reduces the risk of product recalls, regulatory fines, or production stoppages that can hurt revenue and company value, and it supports market access and long-term trust.

bacteriophage therapeutics medical

"development of high-purity, pathogen-specific bacteriophage therapeutics"

Bacteriophage therapeutics are medicines made from viruses that specifically infect and kill bacteria; think of them as guided missiles that seek out harmful bacteria rather than blanket antibiotics that act like area bombs. They matter to investors because they offer a potential solution to antibiotic resistance and could open new markets, but they also carry development and regulatory uncertainty, complex manufacturing needs, and reimbursement risk that can affect commercial prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LOS ANGELES, Sept. 10, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Deborah Birx, M.D., Chief Executive Officer, will participate in a corporate presentation at the H.C. Wainwright 28th Annual Global Investment Conference, which is being held in New York from September 14-16, 2026.

Armata's presentation is scheduled for 11:00 am – 11:30 am EDT on Wednesday, September 16, 2026.

To schedule a one-on-one meeting, please contact your H.C. Wainwright representative.

About Armata Pharmaceuticals, Inc.

Armata is a late clinical-stage biotechnology company focused on the development of high-purity pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other important pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage-specific cGMP manufacturing to support full commercialization.

Media Contacts:

At Armata:
Pierre Kyme
ir@armatapharma.com
310-665-2928

Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
212-915-2569

View original content to download multimedia:https://www.prnewswire.com/news-releases/armata-pharmaceuticals-to-participate-in-the-hc-wainwright-28th-annual-global-investment-conference-302873826.html

SOURCE Armata Pharmaceuticals, Inc.

FAQ

How can investors schedule a one-on-one meeting with Armata at the conference?

To schedule a one-on-one meeting with Armata Pharmaceuticals during the H.C. Wainwright 28th Annual Global Investment Conference, attendees are instructed to contact their H.C. Wainwright representative.

What therapeutic area does Armata focus on?

Armata focuses on developing high-purity, pathogen-specific bacteriophage therapeutics to treat antibiotic-resistant and difficult-to-treat bacterial infections, using its proprietary bacteriophage-based technology and in-house phage-specific cGMP manufacturing.